
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 55.8 kDa. The protein migrates as 53-58 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Supplied as 0.2 μm filtered solution in 25 mM MES, 150 mM NaCl, pH6.0 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human DDC, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

The purity of Human DDC, His Tag (Cat. No. DDC-H55H6) is more than 90% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.
Measured by its ability to convert the substrate 3, 4dihydroxy Lphenylalanine (LDopa) to 3, 4dihydroxyphenylethylamine (dopamine). The dopamine product is measured by its absorbance at 340 nm after derivatization with trinitrobenzene sulfonic acid. The specific activity is >1000 pmol/min/µg (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Benserazide Hydrochloride | Approved | Mainland China | Parkinson Disease; Dyskinesias | Shanghai Yishengyuan Pharmaceutical Co Ltd | 1995-01-01 | Dyskinesias; Parkinson Disease | Details | |||
| Carbidopa | MK-486 | Approved | Lodosyn | Mainland China | Parkinson Disease | Nantong Jinghua Pharmaceutical Co Ltd | 1977-04-25 | Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance | Details | |
| Carbidopa/Entacapone/Levodopa | ODM-101; ELC-200 | Approved | Orion Pharma | Trigel, LECIGel, 达灵复, Stalevo, LECIGon | Japan | Parkinson Disease | Novartis Pharma Ag | 2003-06-11 | Parkinson Disease | Details |
| Levodopa/Carbidopa | IPX-054; AP-09004; DM-1992; AP-CDLD; TPI-926; IPX-066; ABT-SLV-187; AP-CD/LD; ND-0612; ND-0680; ND-0612L; ND-0612H; PW-4153; LCIG; ABT-SLV187; IPX-203; CP-012; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) | Approved | Merck Sharp & Dohme Corp | Nacom (imciromab), Nacom retard, Parcopa, Patrome, DopaFuse, Sinemet, Numient, Menesit, Duodopa, Vadova, Rytary, Isicom, Duopa | Mainland China | Parkinson Disease | Jinghua Pharmaceutical Group Co Ltd | 1975-05-02 | Amblyopia; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Diabetes Mellitus; Albinism; Cocaine-Related Disorders; Cognitive Dysfunction; Depressive Disorder, Treatment-Resistant; Albinism, Oculocutaneous; Gait Apraxia; Parkinson Disease; Aphasia, Broca; Stroke; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Depression; Motor Neuron Disease | Details |
| Eladocagene exuparvovec | PTC-AADC | Approved | National Taiwan University, Ptc Therapeutics Inc | Upstaza | United Kingdom | Aromatic amino acid decarboxylase deficiency | Ptc Therapeutics Inc | 2022-07-18 | Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors | Details |
| Carbidopa/Melevodopa | V-1512; GT-1512; CHF-1512; CNP-1512 | Approved | Chiesi Farmaceutici SPA | Sirio | Italy | Parkinson Disease | null | 2003-01-01 | Parkinson Disease | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Buspirone/Carbidopa/Levodopa | Phase 2 Clinical | Universite Laval | Spinal Cord Injuries; Multiple Sclerosis | Details | |
| Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) | WD-1905 | Phase 2 Clinical | Parkinsonian Disorders | Details | |
| Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) | WD-1603 | Phase 2 Clinical | Parkinsonian Disorders | Details | |
| Levodopa/Carbidopa(WD Pharmaceutical) | WD-1804 | Phase 1 Clinical | Parkinsonian Disorders | Details | |
| Levodopa/Carbidopa granule(WD Pharmaceutical) | WD-2010 | Phase 1 Clinical | Parkinsonian Disorders | Details | |
| Ezaladcigene resoparvovec | GZ-404477; AV-201; VY-AADC02; VY-AADC; VY-AADC01 | Phase 1 Clinical | University Of California, Voyager Therapeutics Inc | Aromatic amino acid decarboxylase deficiency; Parkinson Disease | Details |
This web search service is supported by Google Inc.




